The third medical center of PLA General Hospital
Welcome,         Profile    Billing    Logout  
 4 Trials 
14 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
He, Zhisong
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Active, not recruiting
3
528
RoW
TQB2450, Anlotinib, Sunitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Renal Cancer
06/25
12/25
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT06227156: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Recruiting
2
40
RoW
Disitamab Vedotin Injection, DV,RC48
RemeGen Co., Ltd.
Castration-resistant Prostate Cancer
12/25
06/26
RC48-C017, NCT05297552: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Recruiting
2
40
RoW
RC48-ADC, JS001
RemeGen Co., Ltd.
Muscle Invasive Bladder Carcinoma
06/24
02/25
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Recruiting
2
246
RoW
Axitinib plus Toripalimab, nephrectomy
ZHOU FANGJIAN, Pfizer
Renal Cell Carcinoma, Neoadjuvant
07/25
03/26
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
NCT05943379: RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Recruiting
2
85
RoW
RC48-ADC in Combination with gemcitabine
RemeGen Co., Ltd.
NMIBC
12/25
12/26
NCT06732531: Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

Recruiting
1/2
48
RoW
BH011, Docetaxel
Zhuhai Beihai Biotech Co., Ltd
Bladder Cancer, Non Muscle Invasive
12/25
12/25
NCT05405439: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Terminated
1/2
39
RoW
TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
07/23
07/23
NCT05410730: A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC

Recruiting
1/2
150
RoW
SHR-1501
Shanghai Hengrui Pharmaceutical Co., Ltd.
High-risk NMIBC
05/25
05/27
NCT05393427: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

Recruiting
1
26
RoW
BL-B01D1
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
06/25
06/25
NCT05973149: Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

Not yet recruiting
1
108
RoW
QLH12016
Qilu Pharmaceutical Co., Ltd.
Prostate Cancer
08/25
01/26
Xu, Quangang
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Recruiting
2/3
132
RoW
B001, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Neuromyelitis Optica Spectrum Disorders
10/27
02/29
Li, Weiping
NCT04794972: A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Recruiting
1
147
RoW
GNC-039
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc.
Recurrent Glioma, Solid Tumor
06/25
06/25

Download Options